Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)

Zhongyan Wang; Chuanrui Ma; Yuna Shang; Lijun Yang; Jing Zhang; Cuihong Yang; Chunhua Ren; Jinjian Liu; Guanwei Fan; Jianfeng Liu

doi:10.1039/d0cc00513d

journal article Jan 01, 2020

Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)

Zhongyan Wang

Chuanrui Ma Yuna Shang Lijun Yang

Chemical Communications Vol. 56 No. 36 pp. 4922-4925 · Royal Society of Chemistry (RSC)

View at Publisher Save 10.1039/d0cc00513d

Abstract

An ingenious co-assembled nanosystem based on fenofibrate and ketoprofen peptide for the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses.

Topics

No keywords indexed for this article. Browse by subject →

References

32

[1]

Farrell Hepatology (2006) 10.1002/hep.20973

[2]

Paris Eur. J. Gastroenterol. Hepatol. (2017) 10.1097/meg.0000000000000890

[3]

Angulo N. Engl. J. Med. (2002) 10.1056/nejmra011775

[4]

Remmerie Cell. Immunol. (2018) 10.1016/j.cellimm.2018.01.020

[5]

Rinella JAMA, J. Am. Med. Assoc. (2015) 10.1001/jama.2015.5370

[6]

Younossi Clin. Liver Dis. (2018) 10.1016/j.cld.2017.08.001

[7]

Szabo Nat. Rev. Gastroenterol. Hepatol. (2015) 10.1038/nrgastro.2015.94

[8]

World Gastroenterology Organisation Global Guidelines

Douglas R. LaBrecque, Zaigham Abbas, Frank Anania et al.

Journal of Clinical Gastroenterology 2014 10.1097/mcg.0000000000000116

[9]

Harano Liver Int. (2006) 10.1111/j.1478-3231.2006.01265.x

[10]

Chawla Nat. Med. (2001) 10.1038/83336

[11]

Franceschini Atherosclerosis (2007) 10.1016/j.atherosclerosis.2006.10.017

[12]

Du Chem. Rev. (2015) 10.1021/acs.chemrev.5b00299

[13]

Han Anal. Chem. (2016) 10.1021/acs.analchem.6b00023

[14]

Wang Theranostics (2020) 10.7150/thno.39132

[15]

A multiphase transitioning peptide hydrogel for suturing ultrasmall vessels

Daniel J. Smith, Gabriel A. Brat, Scott H. Medina et al.

Nature Nanotechnology 2016 10.1038/nnano.2015.238

[16]

Shigemitsu Nat. Nanotechnol. (2018) 10.1038/s41565-017-0026-6

[17]

Xing Adv. Mater. (2019) 10.1002/adma.201900822

[18]

Shang Nano Lett. (2019) 10.1021/acs.nanolett.8b04406

[19]

Mondal J. Am. Chem. Soc. (2018) 10.1021/jacs.8b10289

[20]

Wang Chem. Commun. (2018) 10.1039/c8cc01082j

[21]

Cai J. Am. Chem. Soc. (2017) 10.1021/jacs.6b12322

[22]

Feng Chem (2019) 10.1016/j.chempr.2019.06.020

[23]

Wang Angew. Chem., Int. Ed. (2018) 10.1002/anie.201712834

[24]

Ren ACS Appl. Mater. Interfaces (2019) 10.1021/acsami.9b12530

[25]

Kiran Chem. Commun. (2018) 10.1039/c7cc09365a

[26]

Tang ACS Nano (2018) 10.1021/acsnano.8b04143

[27]

Jamali Clin. Pharmacokinet. (1990) 10.2165/00003088-199019030-00004

[28]

Li J. Am. Chem. Soc. (2012) 10.1021/ja310019x

[29]

Wang Nanoscale (2017) 10.1039/c7nr04990k

[30]

Wang Chem. Commun. (2015) 10.1039/c5cc03835a

[31]

Hsieh Obesity (2009) 10.1038/oby.2008.674

[32]

Seo J. Gastroenterol. Hepatol. (2008) 10.1111/j.1440-1746.2006.04819.x

Metrics

18

Citations

32

References

Details

Published: Jan 01, 2020
Vol/Issue: 56(36)
Pages: 4922-4925
License: View

Authors

Z

Zhongyan Wang

Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine; Institute of Radiation Medicine; Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin 300192; P. R. China

C

Chuanrui Ma

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome; Tianjin 300381; P. R. China

Y

Yuna Shang

College of Life Sciences; Nankai University; Tianjin 300071; P. R. China

L

Lijun Yang

Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine; Institute of Radiation Medicine; Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin 300192; P. R. China

J

Jing Zhang

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome; Tianjin 300381; P. R. China

C

Cuihong Yang

Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine; Institute of Radiation Medicine; Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin 300192; P. R. China

C

Chunhua Ren

Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine; Institute of Radiation Medicine; Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin 300192; P. R. China

J

Jinjian Liu

Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine; Institute of Radiation Medicine; Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin 300192; P. R. China

G

Guanwei Fan

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome; Tianjin 300381; P. R. China

J

Jianfeng Liu

Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine; Institute of Radiation Medicine; Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin 300192; P. R. China

Funding

National Natural Science Foundation of China Award: 31900998

Natural Science Foundation of Tianjin City Award: 19JCQNJC12600

Cite This Article

Zhongyan Wang, Chuanrui Ma, Yuna Shang, et al. (2020). Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD). Chemical Communications, 56(36), 4922-4925. https://doi.org/10.1039/d0cc00513d

Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)

You May Also Like